E. Kurosaki

发表

The novel hypoglycemic agent YM440 improves hepatic insulin resistance in obese Zucker fatty rats.

A. Shimaya, M. Shibasaki, R. Nakano, 2006, Journal of pharmacological sciences.

Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice

T. Takasu, A. Tahara, E. Kurosaki, 2017, European journal of pharmacology.

The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.

H. Minoura, S. Takakura, T. Takasu, 2017, Biological & pharmaceutical bulletin.

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice.

T. Takasu, A. Tahara, E. Kurosaki, 2016, Journal of pharmacological sciences.

YM440, a novel hypoglycemic agent, protects against nephropathy in Zucker fatty rats via plasma triglyceride reduction.

A. Shimaya, M. Shibasaki, S. Kajikawa, 2006, European journal of pharmacology.

Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution

T. Takasu, A. Tahara, E. Kurosaki, 2018, European journal of pharmacology.

Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.

E. Kurosaki, H. Ogasawara, 2013, Pharmacology & therapeutics.

Hypoglycemic agent YM440 suppresses hepatic glucose output via gluconeogenesis by reducing glucose-6-phosphatase activity in obese Zucker rats.

K. Momose, A. Shimaya, M. Shibasaki, 2003, European journal of pharmacology.

Hypoglycemic agent YM440 ameliorates the impaired hepatic glycogenesis after glucose loading by increasing glycogen synthase activity in obese Zucker rats.

K. Momose, A. Shimaya, M. Shibasaki, 2002, Japanese journal of pharmacology.

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats.

M. Sasamata, Y. Uchiyama, Hiroshi Tomiyama, 2014, European journal of pharmacology.

In vivo effects of pioglitazone on uncoupling protein-2 and -3 mRNA levels in skeletal muscle of hyperglycemic KK mice.

T. Shimokawa, Y. Watanabe, S. Hashimoto, 1998, Biochemical and biophysical research communications.

Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.

S. Takakura, T. Takasu, E. Kurosaki, 2015, European journal of pharmacology.

clinically-used ARBs: drug-target interaction analyses

M. Orita, Tomohiko Yamaguchi, H. Masuzaki, 2014 .

Distinct Properties of Telmisartan on Agonistic Activities for Peroxisome Proliferator-Activated Receptor γ among Clinically Used Angiotensin II Receptor Blockers: Drug-Target Interaction Analyses

M. Orita, Tomohiko Yamaguchi, H. Masuzaki, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Effect of YM-126414 on glucose uptake and redistribution of glucose transporter isotype 4 in muscle cells.

T. Shimokawa, M. Shibasaki, M. Katoh, 2000, European journal of pharmacology.

YM268 increases the glucose uptake, cell differentiation, and mRNA expression of glucose transporter in 3T3-L1 adipocytes.

A. Shimaya, M. Shibasaki, H. Shikama, 1998, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.

Atsushi Noda, Hiroshi Tomiyama, M. Takeuchi, 2012, Bioorganic & medicinal chemistry.

Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: discovery of YM543.

Atsushi Noda, M. Takeuchi, Takayuki Suzuki, 2013, Bioorganic & medicinal chemistry.

Effects of sodium‐glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin‐induced type 1 diabetic rats

M. Sasamata, Atsushi Noda, Rumi Kihara, 2014, The Journal of pharmacy and pharmacology.

Pharmacological Characterization of YM543, a Newly Synthesized, Orally Active SGLT2 Selective Inhibitor

Atsushi Noda, Rumi Kihara, M. Shibasaki, 2013, Endocrine research.

Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo

M. Sasamata, Atsushi Noda, Rumi Kihara, 2012, Naunyn-Schmiedeberg's Archives of Pharmacology.

Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo.

S. Yoshida, A. Shimaya, M. Shibasaki, 2006, Biochemical pharmacology.

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.

T. Takasu, A. Tahara, E. Kurosaki, 2016, Journal of pharmacological sciences.

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.

M. Sasamata, Atsushi Noda, Rumi Kihara, 2013, European journal of pharmacology.

Hypotensive action of Nangapiry, a Paraguayan natural medicine, in rodents.

H. Nojima, Y. Momose, Y. Kuraishi, 2000, Phytomedicine : international journal of phytotherapy and phytopharmacology.

Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice.

Hiroshi Tomiyama, Atsushi Noda, M. Sasamata, 2012, Journal of pharmacological sciences.

Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice

T. Takasu, A. Tahara, E. Kurosaki, 2016, Archives of pharmacal research.

Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation.

S. Yoshida, A. Shimaya, M. Shibasaki, 2003, Biochemical pharmacology.

Glucose uptake stimulator YM‐138552 activates gene expression and translocation of glucose transporter isotype 4

T. Shimokawa, Y. Ueda, M. Shibasaki, 2000 .

Distinct Properties of Telmisartan on Agonistic Activities for Peroxisome Proliferator-Activated Receptor γ among Clinically Used Angiotensin II Receptor Blockers: Drug-Target Interaction Analyses

M. Orita, Tomohiko Yamaguchi, H. Masuzaki, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo

M. Sasamata, Atsushi Noda, Rumi Kihara, 2011, Naunyn-Schmiedeberg's Archives of Pharmacology.

Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice

T. Takasu, A. Tahara, E. Kurosaki, 2015, Archives of Pharmacal Research.